Valley Radiotherapy Associates Medical Group and Vantage Oncology Announces Joint Venture to Form Glendale Radiation Therapy Center - Vantage Oncology to Implement Facility and Technology Upgrades to Cancer Center

GLENDALE, CA. (June 20, 2008) – In its continued efforts to provide innovative radiation therapy treatment to Glendale cancer patients, Valley Radiotherapy Associates Medical Group, Inc. (VRA) has announced a new partnership with Vantage Oncology, a Manhattan Beach, Calif.-based developer and operator of state-of-the-art radiation oncology centers, to form Vantage Oncology Glendale Radiation Therapy Center. The center will be located on the campus of Glendale Memorial Hospital in the Cancer Center building. Vantage Oncology will provide facility and technology upgrades to the cancer center. The remodeled cancer center is scheduled to be completed in July of 2008.

The renovated Glendale Radiation Therapy Center will feature a remodeled front office and have access to a new patient resource area within the main waiting room. The patient resource center will allow patients and their loved ones a quiet, private place to research their cancer and treatment options on the Internet, and have access to the latest educational materials from the American Cancer Society.

The Glendale Radiation Therapy Center is equipped with a Varian Clinac® 21EX linear accelerator, delivering Intensity Modulated Radiation Therapy (IMRT). In conjunction with Glendale Memorial Hospital, the center will also provide High-Dose Rate (HDR) Brachytherapy. “New technologies such as IMRT help to deliver higher doses of radiation with fewer complications and side effects,” said Linas Kazlauskas, M.D., Medical Director of Glendale Radiation Therapy Center. “With the multi-disciplinary approach to treating malignancies today, our technology will undoubtedly result in optimal results for the patient.”  

IMRT is an advanced clinical treatment option for precisely targeting the tumor with greater doses of radiation, sparing critical normal tissues, providing for better outcomes and fewer side effects for patients. As a result, patients are exposed to less radiation overall, thereby helping to preserve healthy tissue and decreasing potential side effects. HDR Brachytherapy allows the delivery of a high dose of radiation to a small area from within the body tissues, while sparing the surrounding normal tissue.

“The joint venture between Valley Radiotherapy Associates and Vantage Oncology will provide patients of Glendale with access to state-of-the-art diagnostic and radiation therapy services,” said Michael T. Fiore, CEO of Vantage Oncology.  “In combination with the expertise of the physicians and clinical staff, I am confident that our team of experts can effectively educate and treat the patients who have entrusted us with their health.”

ABOUT VANTAGE ONCOLOGY, INC.
Founded in October 2002, Manhattan Beach, California-based Vantage Oncology, Inc. acquires, joint ventures, develops and operates state-of-the-art radiation oncology centers.  Vantage Oncology was created in response to the growing need among cancer patients, hospitals and physicians for accessible and advanced radiation treatment therapies.  Vantage Oncology is led by a seasoned management team, including Chief Executive Officer Michael Fiore, Medical Director Leslie Botnick, M.D., Chief Financial Officer Marshal Salomon and Chief Development Officer Mark Ahern.  For more information about Vantage Oncology, visit www.vantageoncology.com.

ABOUT VALLEY RADIOTHERAPY ASSOCIATES MEDICAL GROUP, INC.
Valley Radiotherapy Associates Medical Group, Inc. (VRA) was founded by Leslie E. Botnick, M.D. and Christopher M. Rose, M.D. in June, 1983 to deliver radiation oncology services. Today, Manhattan Beach, Calif.-based VRA has 34 board-certified radiation oncologists and provides advanced radiation therapy services to communities at 17 hospitals and freestanding centers in Los Angeles, Orange, Riverside, Imperial Valley and San Bernardino Counties in California and Denver, Colorado. VRA has distinguished itself during the past 25 years as one of the premier radiation oncology groups in the nation with a proven record of excellence in clinical treatment, superiority in service delivery and technical acumen to develop new cancer treatment programs.  For more information about VRA, visit  www.valley-radiotherapy.com.

CONTACT:            

Trace Longo
Longo Communications
(949) 364-2821 

Vantage Oncology, Marketing Dept.
email:info@vantageoncology.com